Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease.

IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Forum Pub Date : 2023-01-01 DOI:10.14744/hf.2022.2022.0042

Tansu Eris, Moomen Hassan, Yousra Hikal, Enas Sawah, Fatemeh Daneshgar, Ayse Gulsen Teker, Furkan Ozel, Nimet Emel Luleci, Eda Kaya, Yusuf Yilmaz

{"title":"Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease.","authors":"Tansu Eris, Moomen Hassan, Yousra Hikal, Enas Sawah, Fatemeh Daneshgar, Ayse Gulsen Teker, Furkan Ozel, Nimet Emel Luleci, Eda Kaya, Yusuf Yilmaz","doi":"10.14744/hf.2022.2022.0042","DOIUrl":null,"url":null,"abstract":"Background and aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. FibroScan® is used for follow-up of fibrosis and steatosis. This single-center study aims to review the distribution of indications by referral to FibroScan®.Materials and methods: Demographic characteristics, CLD etiologies, and FibroScan® parameters of the patients who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated.Results: Out of 9345 patients, 4946 (52.93%) were males, and the median age was 48 [18-88] years. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N=4768, 51.02%), followed by hepatitis B (N=3194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, and CLD etiology, the results revealed that patients with older age (Odds ratio (OR)=2.908; confidence interval (CI)=2.597-3.256; p<0.001) and patients with hepatitis C (OR=2.582; CI=2.168-3.075; p<0.001), alcoholic liver disease (OR=2.019; CI=1.524-2.674, p<0.001), and autoimmune hepatitis (OR=2.138; CI=1.360-3.660, p<0.001) had increased odds of advanced liver fibrosis compared to NAFLD.Conclusion: NAFLD was the most common indication for referral to FibroScan®.","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/69/hf-4-007.PMC9951899.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/hf.2022.2022.0042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background and aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. FibroScan^® is used for follow-up of fibrosis and steatosis. This single-center study aims to review the distribution of indications by referral to FibroScan^®.

Materials and methods: Demographic characteristics, CLD etiologies, and FibroScan^® parameters of the patients who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated.

Results: Out of 9345 patients, 4946 (52.93%) were males, and the median age was 48 [18-88] years. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N=4768, 51.02%), followed by hepatitis B (N=3194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, and CLD etiology, the results revealed that patients with older age (Odds ratio (OR)=2.908; confidence interval (CI)=2.597-3.256; p<0.001) and patients with hepatitis C (OR=2.582; CI=2.168-3.075; p<0.001), alcoholic liver disease (OR=2.019; CI=1.524-2.674, p<0.001), and autoimmune hepatitis (OR=2.138; CI=1.360-3.660, p<0.001) had increased odds of advanced liver fibrosis compared to NAFLD.

Conclusion: NAFLD was the most common indication for referral to FibroScan^®.

Abstract Image

查看原文本刊更多论文

转介到纤维扫描中心的慢性肝病病因学的变化:非酒精性脂肪性肝病的患病率增加。

背景和目的:慢性肝病(CLD)是世界范围内发病率和死亡率的主要原因，病因广泛。FibroScan®用于纤维化和脂肪变性的随访。本单中心研究旨在回顾转诊至FibroScan®的适应症分布。材料和方法:回顾性评估2013年至2021年间转介至我们三级护理中心的患者的人口统计学特征、CLD病因学和FibroScan®参数。结果:9345例患者中，男性4946例(52.93%)，中位年龄48岁[18-88]岁。非酒精性脂肪性肝病(NAFLD)是最常见的适应症(N=4768, 51.02%)，其次是乙型肝炎(N=3194, 34.18%)和丙型肝炎(N=707, 7.57%)。调整年龄、性别和CLD病因后，结果显示年龄较大的患者(优势比(OR)=2.908;置信区间(CI)=2.597-3.256;结论:NAFLD是转诊至FibroScan®的最常见适应症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology Forum

CiteScore

1.90

自引率

12.50%

发文量